Epstein-Barr virus antigen-peptide-MHC complex (EBV-pMHC)

Peptide-MHC (pMHC) complexes presenting Epstein-Barr virus (EBV) antigens are critical molecular targets on the surface of host cells, representing the primary mechanism by which the immune system identifies EBV-infected or transformed cells (Taylor et al., 2015, Nature Reviews Immunology). These complexes are formed when viral proteins, such as Latent Membrane Proteins (LMP1, LMP2) or Epstein-Barr Nuclear Antigens (EBNA), are processed into short peptides and loaded onto Major Histocompatibility Complex (MHC) molecules, primarily HLA Class I (Hislop et al., 2007, Annual Review of Immunology). Their biological role is to serve as ligands for T-cell receptors (TCRs) on CD8+ cytotoxic T lymphocytes, triggering an immune response against the host cell (Long et al., 2011, Trends in Microbiology). In clinical contexts, these complexes are targeted to treat EBV-associated malignancies like post-transplant lymphoproliferative disorder (PTLD) and nasopharyngeal carcinoma (Prockop et al., 2020, JCI). Therapeutic strategies include adoptive cell therapies like tabelecleucel (Ebvallo), which uses allogeneic EBV-specific T cells to recognize these pMHC targets (Dharnidharka et al., 2022, American Journal of Transplantation). Additionally, engineered TCR-T cells and TCR-like antibodies are being developed to target specific EBV peptides, such as those from LMP2A, presented by common HLA alleles like HLA-A*02:01 (Lin et al., 2022, Blood). Challenges in targeting EBV-pMHC include the high diversity of HLA alleles across populations, which limits the applicability of specific therapies, and the risk of cross-reactivity with self-peptides, which can lead to off-target toxicity (Bollard & Heslop, 2016, Blood). Furthermore, EBV can employ immune evasion tactics, such as downregulating MHC expression, to avoid detection by these T-cell-based therapies (Ressing et al., 2015, Current Opinion in Virology).

Other names

EBV peptide-HLA complexEpstein-Barr virus peptide-major histocompatibility complexEBV-pMHCEBV-specific pMHCEBV antigen-MHC complex

Targeting and binding of T-cell receptors (TCRs) to the peptide-MHC complex, leading to the activation of cytotoxic T-cell responses and subsequent lysis of EBV-positive cells.